<unk>  is an tyrosine kinase inhibitor that is FDA approved for the treatment of symptomatic or progressive medullary thyroid cancer.   Common adverse reactions include diarrhea, nausea, fatigue, rash, headache, abdominal pain, dyspepsia, hypocalcemia, cough, depression.
Vandetanib
Masitinib
Toceranib
Semaxanib
Alectinib
Pegaptanib
Enasidenib
Cediranib